Amgen CFO Peacock takes flight; Galectin raises $32M for R&D work;

@FierceBiotech: MannKind has an FDA advisory committee review of Afrezza set for April 1. Release | Follow @FierceBiotech

@JohnCFierce: 1 of today's top stories: Ex-$BMS R&D chief Sigal makes the leap into venture finance. Joins Mott at NEA. Story | Follow @JohnCFierce

@DamianFierce: Analyst says Lombard's U.S. IPO could come in at $70M. EP Vantage story | Follow @DamianFierce

@EmilyMFierce: Blast at San Francisco Amgen lab injures 2. Story | Follow @EmilyMFierce

> Jonathan Peacock, the CFO at Amgen ($AMGN), is leaving his post to go after some "broader career opportunities." Story

> Galectin Therapeutics in Norcross, GA, has raised $32.3 million for its work on drugs for fibrosis and cancer. Release

Medical Device News

@FierceMedDev: St. Louis spinal/sports medicine co. ISTO Technologies names George Dunbar CEO. Release | Follow @FierceMedDev

@MichaelGFierce: Global nanomed market, driven by brain delivery, is expected to reach $177B by 2019. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: How much is that artificial hip? Your doctor probably doesn't know. Story | Follow @EmilyWFierce

@MarkHFierce: Three heavy-hitters--Covidien, NEA and Lightstone--are jointly investing in a new Irish med tech company. Release | Follow @MarkHFierce

> PureTech's Tal Medical faces a clinical test of its rapid depression treatment. Editor's corner

> Endo finally ditches its urology tech business for up to $130M. More

> Inspire Medical's sleep apnea implant scores for majority in study. Story

Pharma News

@FiercePharma: Best-read FiercePharma special yesterday: Top 10 Drug Patent Losses of 2014. Report | Follow @FiercePharma

@TracyStaton: Top FiercePharma news Thursday: Wanna trade? Novartis + Merck reportedly negotiating $5B unit swap. Story | Follow @TracyStaton

@EricPFierce: Genentech liquid Tamiflu delays stem from packaging issues. Shortages possible but capsules available. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: With CEO pick, Teva bets turnaround savvy will trump pharma know-how. Thursday's story | Follow @CarlyHFierce

> DOJ wants Aegerion to talk about what it's been saying. Story

> KV gets a second shot at forcing the FDA to restrict compounders on Makena. Article

> Shire not quite to the finish line with ViroPharma. More

> C-suite shuffle: Amgen CFO Peacock resigns. Item

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.